Method for promoting soluble expression of tafa4 and application thereof
By constructing the Trx-TAFA4 fusion protein in the E. coli expression system and optimizing the induction conditions, the problem of low TAFA4 protein yield was solved, achieving efficient and low-cost large-scale production and high-purity protein preparation, which has significant immunomodulatory effects.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- WEST CHINA HOSPITAL SICHUAN UNIV
- Filing Date
- 2026-03-24
- Publication Date
- 2026-06-02
AI Technical Summary
The large-scale production of TAFA4 protein in existing technologies faces problems such as low yield, high cost, long cycle and risk of viral contamination, especially in E. coli expression systems where the protein yield of commonly used plasmids is low.
The Trx-TAFA4 fusion protein was cloned and expressed in an E. coli expression vector. By optimizing the induction conditions and purification process, the pET32a-TAFA4 expression plasmid was constructed, transformed into E. coli BL21(DE3), and then IPTG-induced expression and nickel gel purification were performed to obtain high-purity Trx-TAFA4 fusion protein.
The method significantly improved the soluble expression yield of TAFA4 protein. It is simple, rapid, and low-cost, and has a high advantage for large-scale production. Furthermore, the purified Trx-TAFA4 fusion protein has significant immunomodulatory activity against macrophages.
Smart Images
Figure CN122127487A_ABST